Allergan ($AGN) is mired in a fight to remain independent from serial acquirer Valeant ($VRX), so having to tell investors it received a complete response letter (CRL ...

Novartis’ Zolgensma launch has been anything but boring: First a record-setting price tag, then a data-manipulation scandal and, with Tuesday earnings, a Street-beating first quarter on the market.

Originally published by Charles Duhigg on LinkedIn: How Asking 5 (Lean Manufacturing) Questions Helped Me Eat Dinner With My Kids Four years ago, when I began working on a book about the secrets of ...

Opinions expressed by Entrepreneur contributors are their own. “Do you know a place to get this made?” That’s a question I hear a lot from entrepreneurs looking for a manufacturing solution. It’s ...

Large companies that were early adopters and evangelize its transformative benefits Smaller manufacturers who are cautiously trying to determine if AM is worth the investment. Because the group of ...